|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
13
|
|
pubmed:dateCreated |
1976-8-23
|
|
pubmed:abstractText |
Thirty patients with classical or definite rheumatoid arthritis were treated over a 4-week period with diftalone, a new non-steroidal antirheumatic drug. The daily dosage ranged from 500 to 1000 mg. A good objective response was achieved in 69% of the patients. Diftalone was well tolerated. Side effects were noted in 11.8% of patients on 500 mg diftalone daily and in 18.8% of cases treated with the highest dosage (1000 mg daily). The optimum daily dosage appears to be 750 mg.
|
|
pubmed:language |
ger
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0043-5325
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
27
|
|
pubmed:volume |
87
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
427
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:779281-Administration, Oral,
pubmed-meshheading:779281-Adult,
pubmed-meshheading:779281-Anti-Inflammatory Agents,
pubmed-meshheading:779281-Arthritis, Rheumatoid,
pubmed-meshheading:779281-Blood Sedimentation,
pubmed-meshheading:779281-Clinical Trials as Topic,
pubmed-meshheading:779281-Female,
pubmed-meshheading:779281-Humans,
pubmed-meshheading:779281-Male,
pubmed-meshheading:779281-Middle Aged,
pubmed-meshheading:779281-Phthalazines,
pubmed-meshheading:779281-Placebos,
pubmed-meshheading:779281-Pyridazines
|
|
pubmed:year |
1975
|
|
pubmed:articleTitle |
[Preliminary results with a new non-steroidal antirheumatic drug (author's transl)].
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
English Abstract
|
